632325-71-4
632325-71-4
Chemical Structure
Cyclopropavir
Synonym(s): Filociclovir; ZSM-I-62; MBX-400
- CAS No.: 632325-71-4
- Formula:C11H13N5O3
- Molecular Weight:263.26
IUPAC Name: (E)-2-amino-9-((2,2-bis(hydroxymethyl)cyclopropylidene)methyl)-3,9-dihydro-6H-purin-6-one
InChIKey: KMUNHOKTIVSFRA-QHHAFSJGSA-N
SMILES: OCC(/C1=C/N2C3=C(C(N=C(N)N3)=O)N=C2)(C1)CO
Biological Activity: Cyclopropavir (Filociclovir) is an orally active and broad-spectrum anti-herpesvirus compound. Cyclopropavir inhibits UL97 kinase activity. Cyclopropavir has antiviral activity against HCMV, MCMV, and HAdV6 viruses[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cyclopropavir | 98.0% | Cyclopropavir (Filociclovir) is an orally active and broad-spectrum anti-herpesvirus compound. Cyclopropavir inhibits UL97 kinase activity. Cyclopropavir has antiviral activity against HCMV, MCMV, and HAdV6 viruses. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kern ER, et al. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother. 2005 Mar;49(3):1039-45. [Content Brief]
- [2]. James SH, et al. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother. 2011 Oct;55(10):4682-91. [Content Brief]
- [3]. Gentry BG, et al. Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells. Antimicrob Agents Chemother. 2014;58(4):2329-33. [Content Brief]
- [4]. Kern ER, et al. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother. 2004 Dec;48(12):4745-53. [Content Brief]
- [5]. Toth K, et al. Filociclovir Is a Potent In Vitro and In Vivo Inhibitor of Human Adenoviruses. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01299-20. [Content Brief]
